ATCC Licensed Derivative™ Program Expands
Worldwide Reach with Addition of Gibson Labs
March 8, 2006

ATCC announced today the addition of Kentucky-based Gibson Laboratories, Inc. to the ATCC Licensed Derivative™ (LD) program. With the Gibson agreement, the LD program now benefits thousands of quality control professionals who use commercial microbiology products at hospitals and laboratories in 36 countries.

Launched by ATCC in June 2005, the LD program establishes a mechanism to confirm the identity, viability and purity of microbes contained in commercial microbiology products sold by members of the program. Quality control professionals as well as consumers are assured that products bearing ATCC's Licensed Derivative emblem contain microorganisms tested by ATCC to ensure they are viable, pure and accurately identified.

Gibson Laboratories, an established provider of microbiology supplies, is the third company to join the ATCC Licensed Derivative program in recent months. The other companies involved in the program are Minnesota-based MicroBioLogics Inc., which joined in June 2005, and Quality Technologies LLC of California, a member since November 2005.

"We are delighted that Gibson has joined the roster of LD program firms," Jesus Soriano, MD/PhD, ATCC Vice President for Licensing, Contracts and Compliance remarked. "The reach of the Licensed Derivative program is expanding, and professionals responsible for microbiology testing have more of an opportunity than ever to take advantage of the extra confidence that comes with the verified microorganisms in LD products."